Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapeutics based on RNA interference (RNAi). Its development programs include ALN-RSV01, a phase I human clinical trial product for the treatment of respiratory syncytial virus (RSV) infection; ALN-FLU01 for pandemic influenza; and ALN-PCS01 for the treatment of hypercholesterolemia with an RNAi therapeutic. The company also engages in pre-clinical discovery programs for RNAi therapeutics for the treatment of Parkinson's disease, Huntington's disease, neuropathic pain, progressive multifocal leukoencephalopathy, Ebola virus infection, and cystic fibrosis. It has strategic alliances with Merck & Co., Inc.; Medtronic, Inc.; and Novartis and Biogen Idec, Inc. for the development and commercialization of RNA interference system products. Alnylam also has contracts with government agencies, including the National Institute of Allergy and Infectious Diseases. In addition, it has license agreements with biotechnology companies, which engage in developing RNAi therapeutic products; and research companies that commercialize RNAi reagents or services. Further, the company has collaboration agreements with Medtronic, Inc. for the development of drug-device products to treat diseases caused by degeneration of the nervous system; and Biogen Idec, Inc. for research on the use of RNAi technology to discover and develop therapeutics to treat PML. It also has collaboration agreements with Novartis Pharma AG to develop RNAi therapeutics for pandemic flu; University of Texas Southwestern to develop RNAi therapeutics targeting proprotein convertase subtilisn/kexin type 9; and Inex Pharmaceuticals Corporation for the discovery, development, and commercialization of RNAi therapeutics. The company was founded in 2002 and is based in Cambridge, Massachusetts.
Gallery View 4: (Full Sto, MACD, Aroon8)